Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
The SAPIEN M3 system (Edwards Lifesciences) is the first commercially available device for transeptal transcatheter mitral valve replacement (TMVR), following the positive results of the ENCIRCLE trial [1]. Since its approval, it has been used to treat the whole spectrum of mitral valve disease, and the complexity of the cases undertaken by physicians worldwide has increased, expanding to patients with anatomic features that were not included in the trial.
History of Presentation A 88-year-old man was followed at our clinic because of severe aortic stenosis, which became symptomatic with angina and dyspnea on exertion. • Attention must be paid to avoid left ventricle wire loss during the transcatheter aortic valve replacement procedure, especially when using a nonretrievable device.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
